Ionis Pharmaceuticals Inc (IONS)

[popeyemag]

Looking strong and holding up nice today. Grabbing Sept 16th $30 calls. GL longs!

[seasonedwell]

We are the leading company in RNA-targeted drug discovery and development with a pipeline of first-in-class or best-in-class medicines with the potential to provide high value for patients with significant unmet medical needs. We have created an efficient and broadly applicable drug discovery platform. Using this platform, we believe that we are revolutionizing medicine with the goal to improve the quality of, and save, lives.

We have discovered and are developing three potentially transformational drugs, nusinersen, IONIS-TTRRx and volanesorsen, which we believe are close to commercialization. We designed each of these three drugs to treat patients with orphan diseases who have limited or no therapeutic options. In total, we are developing these three drugs for six different patient populations. In 2015, we completed target enrollment in the first pivotal Phase 3 study for each of these three drugs, and we anticipate reporting data from these studies in the first half of 2017. We designed nusinersen to treat patients with spinal muscular atrophy, or SMA, a severe motor-neuron disease that is the leading genetic cause of infant mortality. We designed IONIS-TTR Rx  to treat patients with transthyretin amyloidosis, or TTR amyloidosis, a fatal disease in which patients experience progressive buildup of amyloid plaque deposits in tissues throughout the body, including peripheral nerves, heart, intestinal tract, kidney and bladder. We designed volanesorsen to treat patients with diseases associated with extremely high levels of triglycerides, including patients with two severe and rare genetic conditions called familial chylomicronemia syndrome, or FCS, and patients with familial partial lipodystrophy, or FPL. We anticipate that the data from our pivotal Phase 3 studies of these drugs, if positive, will support global regulatory filings for each drug. We believe that the significant unmet medical need and the severity of these diseases could warrant a rapid path to market. Already our partners for these programs, Biogen for nusinersen and GSK for IONIS-TTR Rx , are preparing to commercialize these drugs. Our wholly owned subsidiary, Akcea Therapeutics Inc., or Akcea, is preparing to commercialize volanesorsen. All three companies are engaging in pre-commercialization activities to understand the patient journey, build disease awareness with physicians and patients and develop their launch plans. We believe all three of these drugs have the potential to reach the market in the next several years.

To maximize the value of volanesorsen and other earlier-stage drugs for serious cardiometabolic disorders, we formed Akcea Therapeutics to focus on developing and commercializing these drugs. Akcea’s pipeline includes volanesorsen, IONIS-APOCIII-L Rx , IONIS-APO(a)-L Rx  and IONIS-ANGPTL3-L Rx . Moving these drugs into a company that we own and control allows us to retain substantial value from them and ensures Ionis’ core focus remains on innovation. Akcea is building development and commercialization expertise in lipid and cardiometabolic diseases, including highly trained, specialized medical, marketing and sales teams, to successfully commercialize volanesorsen and the other lipid drugs in its pipeline. To learn more about Akcea Therapeutics, visit Akceatx.com.

[seasonedwell]

Bought 2k today. Looks way too cheap....Paid 22....

[jfkspire]

I just hope the financial report on Feb 25th will have some,,""Awesome News""!!
$$IONS$$

[nimbustux]

Perceval,

The CEO was on Mad Money some time ago. Didn't seem like he had a grip on the questions Kramer was firing at him. That shouldn't matter but your right they a lot on the stove and the sp will move quick when they get there ducks in a row.

GLTA

[jfkspire]

This Stock with 38 drugs in pipeline.
Is way under-valued!!
Pathetic Price of $35!!
The Stock should be trading above $100!!
$$IONS$$

[nimbustux]

stocktrademan

The new symbol (IONS) is now on Investor Hub

Pass It On Thanks And Good Luck To All.

[stocktrademan]

$ISIS recent news/filings

bullish optionable 57.74

## source: finance.yahoo.com

Thu, 17 Dec 2015 12:16:19 GMT ~ Isis Pharmaceuticals Announces Initiation of an Investigator-Sponsored Phase 2 Study of ISIS-TTR Rx in Patients with TTR Cardiomyopathy Amyloidosis

[at noodls] - , /PRNewswire/ -- (NASDAQ: ISIS) announced today the initiation of an investigator-sponsored, open-label Phase 2 study evaluating ISIS-TTR in patients with wild-type transthyretin amyloidosis (wt-TTR amyloidosis, ...

read full: http://www.noodls.com/view/2C73D896231DF920130FF75F1B9E99BDAA397641
*********************************************************

Thu, 17 Dec 2015 12:01:00 GMT ~ 7:01 am ISIS Pharm initiates an investigator-sponsored phase 2 study of ISIS-TTR Rx in patients w/ TTR Cardiomyopathy Amyloidosis


read full: http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#isis
*********************************************************

Thu, 17 Dec 2015 12:00:00 GMT ~ Isis Pharmaceuticals Announces Initiation of an Investigator-Sponsored Phase 2 Study of ISIS-TTR Rx in Patients with TTR Cardiomyopathy Amyloidosis

[PR Newswire] - CARLSBAD, Calif., Dec. 17, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (ISIS) announced today the initiation of an investigator-sponsored, open-label Phase 2 study evaluating ISIS-TTRRx in patients with wild-type transthyretin amyloidosis (wt-TTR amyloidosis, previously referred to as senile systemic amyloidosis, or SSA). The Phase 2 study will be conducted by Dr. Rodney Falk, the director of the Cardiac Amyloidosis Program and a cardiovascular medicine specialist at the Brigham and Women's Hospital in Boston. The Phase 2, investigator-initiated study will evaluate treatment with ISIS-TTRRx in approximately 50 patients with wt-TTR amyloidosis. Patients must have evidence of cardiac disease as indicated by an interventricular septum thickness (IVS) of >1.3cm with a positive cardiac biopsy. The effects of ISIS-TTRRx on cardiac disease stabilization will be measured by cardiac imaging at 6, 12 and 18 months. Data from this study will provide additional information on ISIS-TTRRx and can also be included in the robust data package Isis and GSK are generating to support regulatory filings for ISIS-TTRRx in all patients with TTR amyloidosis. For further study information, please visit www.clinicaltrials.gov and search for ISIS-TTRRx.

read full: http://finance.yahoo.com/news/isis-pharmaceuticals-announces-initiation-investigator-120000353.html
*********************************************************

Tue, 15 Dec 2015 14:01:58 GMT ~ Isis Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : December 15, 2015


read full: http://www.capitalcube.com/blog/index.php/isis-pharmaceuticals-inc-breached-its-50-day-moving-average-in-a-bearish-manner-december-15-2015/
*********************************************************

Tue, 15 Dec 2015 01:40:00 GMT ~ Will 2016 Be Alnylam Pharmaceuticals, Inc.'s Best Year Yet?


read full: http://www.fool.com/investing/general/2015/12/14/will-2016-be-alnylam-pharmaceuticals-incs-best-yea.aspx?source=eogyholnk0000001&utm_source=yahoo&utm_medium=feed&utm_campaign=article
*********************************************************

$ISIS charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$ISIS company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/ISIS/company-info
Ticker: $ISIS
OTC Market Place: Not Available
CIK code: 0000874015
Company name: Isis Pharmaceuticals, Inc.
Company website: http://www.isip.com
Incorporated In: DE, USA

$ISIS share structure

## source: otcmarkets.com

Market Value: $7,130,187,147 a/o Dec 16, 2015
Shares Outstanding: 120,117,708 a/o Nov 04, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.001

$ISIS extra dd links

Company name: Isis Pharmaceuticals, Inc.
Company website: http://www.isip.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=ISIS+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=ISIS+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=ISIS+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/ISIS/news - http://finance.yahoo.com/q/h?s=ISIS+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/ISIS/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/ISIS/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=ISIS+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/ISIS
DTCC (dtcc.com): http://search2.dtcc.com/?q=Isis+Pharmaceuticals%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Isis+Pharmaceuticals%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Isis+Pharmaceuticals%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.isip.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.isip.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.isip.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/ISIS
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000874015&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/ISIS/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/ISIS/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=ISIS&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=ISIS
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/ISIS/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=ISIS+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=ISIS+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=ISIS
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=ISIS
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=ISIS+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/ISIS/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=ISIS+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/ISIS.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=ISIS
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/ISIS/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/ISIS
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/ISIS
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/ISIS:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=ISIS
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=ISIS



$ISIS DD Notes ~ http://www.ddnotesmaker.com/ISIS

[stocktrademan]

$ISIS recent news/filings

bullish 62.46

## source: finance.yahoo.com

Tue, 24 Nov 2015 17:24:36 GMT ~ Is People’s United Financial, Inc. (PBCT) Going to Burn These Hedge Funds?


read full: http://www.insidermonkey.com/blog/is-peoples-united-financial-inc-pbct-going-to-burn-these-hedge-funds-387685/
*********************************************************

Tue, 24 Nov 2015 13:42:33 GMT ~ It’s time to lighten the load on these 10 stocks


read full: http://www.marketwatch.com/News/Story/Story.aspx?guid=37AAB526-9188-11E5-8287-6D9A220662B3&siteid=yhoof2
*********************************************************

Fri, 20 Nov 2015 18:00:00 GMT ~ ILIU: Expect Pick-Up In PerioPredict Activity Heading Into 2016


read full: http://finance.yahoo.com/news/iliu-expect-pick-periopredict-activity-180000306.html
*********************************************************

Thu, 19 Nov 2015 19:24:08 GMT ~ Isis was Goddess of Life, and inspiration for Isis Pharmaceuticals


read full: http://finance.yahoo.com/tumblr/blog-isis-was-goddess-of-life-and-inspiration-for-isis-192427379.html
*********************************************************

Wed, 18 Nov 2015 20:21:23 GMT ~ Paris Attacks Prompt Isis Pharmaceuticals to Mull a Name Change


read full: http://www.bloomberg.com/news/articles/2015-11-18/paris-attacks-prompt-isis-pharmaceuticals-to-mull-a-name-change?cmpid=yhoo.headline
*********************************************************

$ISIS charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$ISIS company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/ISIS/company-info
Ticker: $ISIS
OTC Market Place: Not Available
CIK code: 0000874015
Company name: Isis Pharmaceuticals, Inc.
Company website: http://www.isip.com
Incorporated In: DE, USA

$ISIS share structure

## source: otcmarkets.com

Market Value: $7,498,948,510 a/o Nov 25, 2015
Shares Outstanding: 120,117,708 a/o Nov 04, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.001

$ISIS extra dd links

Company name: Isis Pharmaceuticals, Inc.
Company website: http://www.isip.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=ISIS+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=ISIS+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=ISIS+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/ISIS/news - http://finance.yahoo.com/q/h?s=ISIS+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/ISIS/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/ISIS/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=ISIS+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/ISIS
DTCC (dtcc.com): http://search2.dtcc.com/?q=Isis+Pharmaceuticals%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Isis+Pharmaceuticals%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Isis+Pharmaceuticals%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.isip.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.isip.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.isip.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/ISIS
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000874015&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/ISIS/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/ISIS/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=ISIS&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=ISIS
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/ISIS/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=ISIS+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=ISIS+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=ISIS
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=ISIS
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=ISIS+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/ISIS/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=ISIS+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/ISIS.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=ISIS
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/ISIS/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/ISIS
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/ISIS
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/ISIS:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=ISIS
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=ISIS



$ISIS DD Notes ~ http://www.ddnotesmaker.com/ISIS

[KingDMC]

Wow on a rip!

[magness]

ISIS has 38 drugs in pipeline. even 20% success still super good. 1 good drug can bring a biotech stk up 30 40%. ISIS is a LT stks. great buyout potentials due to the pipeline. over $100 , even $200 stk one day..

[expediter13]

Does anyone here have a list of trial data due out in 2015 ?

[KingDMC]

AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases

Source: PR Newswire (US)
CARLSBAD, Calif., Aug. 3, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) and AstraZeneca today announced a strategic collaboration to discover and develop antisense therapies for cardiovascular, metabolic and renal diseases. The new collaboration builds on a broad existing relationship between the two companies and supports AstraZeneca's strategic approach in these therapeutic areas using novel RNA-targeted treatments. It also enables Isis Pharmaceuticals to extend use of its antisense technology to diseases of the kidney.

Isis Pharmaceuticals, Inc.
Antisense drugs are short, chemically modified, single-stranded nucleic acids (antisense oligonucleotides) that have the ability to target any gene product of interest. They offer new opportunities for therapeutic intervention because they act inside the cell to influence protein production by targeting RNA to either prevent the production of disease-causing proteins, increase the production of proteins deficient in disease, or target toxic RNAs that are unable to generate proteins.

AstraZeneca will pay an upfront fee of $65 million to Isis Pharmaceuticals plus development and regulatory milestones for each program that AstraZeneca advances to clinical development. Isis Pharmaceuticals is also eligible to earn tiered double-digit royalties on annual net sales for each program.

Mene Pangalos, Executive Vice President, Innovative Medicines & Early Development at AstraZeneca, said: "Antisense-based therapies are rapidly gaining momentum in the clinic and becoming an important component of our early stage pipeline. This collaboration combines the world-class antisense drug research capabilities of Isis with our expertise in cardiovascular, metabolic and renal disease drug discovery and development. By working together, we aim to uncover targets and pathways that can be manipulated using antisense drug therapy."

B. Lynne Parshall, Chief Operating Officer at Isis Pharmaceuticals, said: "This expansion of our collaboration with AstraZeneca establishes our second strategic relationship. This new collaboration will help broaden the application of our antisense technology to targets in the kidney. AstraZeneca is committed to finding novel best-in-class therapies for some of the largest, most complex and fastest growing disease segments in the developed world. Combining our antisense technology with AstraZeneca's strong knowledge, leadership and commitment in these areas should be very valuable in fully exploiting these opportunities and moving new therapies effectively and efficiently toward the market."

[KingDMC]

I did double down. And then took a loss not long after.

[TREND1]

KING
You got your double down , but no sell yet ?
Or did I miss that post ?

[TREND1]

SEE ISIS on this table below

[TREND1]

ISIS 30 D W M PF 100M

[TREND1]

EPS = -20

[TREND1]

float=100M

[WF]

Cramer says to OWN Apple - don't trade it. I think the same is true of these (better) biotechs.
WF

[kugel]

Cramer had the CEO on last night looking good with what in in pipeline Sold my share,My wife still has a pretty good position..Go team

[KingDMC]

CHXE down below $67.67

[KingDMC]

$75 today I would imagine.

[KingDMC]

In at $68.40. Will double down with a bid at $66.

[kugel]

Here we go again FOLD,and GWPH money flowing like water go team>>

[kugel]

Up we go all the sleepers are on the run money money money..

[kugel]

Hope someone else is making money also, to good to miss,,

[kugel]

Cramer helped us out!

[Dennisb68]

Added 4000 shares to my position. LET IT GO!!!!

[kugel]

Got in just right making money great!!

[kugel]

Got in just in time to watch it go down cost me money jumping in and out who would have thought..

[JPetroInc]

one of Cramers favored here......

[KingDMC]

I missed it. Trying to plan moves here. Scary stuff this market is right now.

[crudeoil24]

Did you buy ISIS 69.00 dip? Some drop. Heading back up!

[crudeoil24]

Ditto!

[GuTA]

Excited for the week ahead. Think the sector will have a good week and have been loving ISIS since it was in the 20s. Here's to hoping we hear something nice from the JPM conference!

[crudeoil24]

Seeing that ISIS partnered up with ALNY today, GILD may acquire ARWR.

http://ih.advfn.com/p.php?pid=nmona&article=65043919

Also:

Gilead Sciences, Inc. (NASDAQ:GILD) Looks Forward To Acquiring Arrowhead Research Corp (NASDAQ:ARWR) 0
BY THOMAS COPELAND ON JANUARY 1, 2015 BIOPHARMA
News has it that Gilead Sciences, Inc. (NASDAQ:GILD) is looking forward to sealing an acquisition deal with Arrowhead Research Corp (NASDQ:ARWR). The company bought a small cap of the latter’s stock, and now it wants to acquire the whole company. According to the news, the healthcare giant wants to acquire Arrowhead for its hepatitis B drugs. The pipeline of Arrowhead is very strong, as it contains ARC-520 drug.

Arrowhead Research Corp (NASDAQ:ARWR) is based in California. The company has a number of important drugs in its pipeline; some of them being the experimental ones. The ARC-520 drug of Arrowhead is being tested for the cure of hepatitis B. Another significant drug that Arrowhead is testing is an anti-obesity one.

Gilead Sciences, Inc. (NASDAQ:GILD) recently bought some stocks in Arrowhead, causing the share price of Arrowhead to go up by 14.5 percent. The average trading volume for 30 day period was recorded to be at 2.23 million; however, the stocks volume reached 11.7 million as soon as Gilead bought the shares.

The stocks of Arrowhead plummeted in the last few months, due to a rough period that the company was going through. The company released a research report on the phase 2 trial study of one of its hepatitis drugs: the results of the study were not very favorable, causing the investors to trade their shares. The results were even weaker than what the company and the analysts were expecting. Some of the investors sought help from law firms and filed suits against the company, alleging that Arrowhead did not reveal the full information about the drug, and thus tricked the investors into investing their money on the experimental drug.

The chief executive of Arrowhead, Christopher Anzalone, on the other hand, is very confident about the company, especially the technology that it is developing in its test units in Madison. According to Christopher, the company has investment in research and development, which is not a bad choice. He further stated that the investments will pay off very soon.

That said, Arrowhead can only afford to lose a few competitions, for the situation in healthcare industry is quite tense at the moment. It is important to mention here that ARC-520 is an RNA interference drug. Gilead Sciences, Inc. (NASDAQ:GILD) has 3 products in its pipeline; however, none of them is an RNA interference drug. The only other company that is developing and RNA interference drug for hepatitis B is Alnylam Pharmaceuticals (NASDAQ:ALNY)

Gilead Sciences, Inc. (NASDAQ:GILD) currently has $6.2 billion cash lying around, so it can surely afford Arrowhead. The acquisition will not only improve its pipeline for hepatitis B drugs but it will also make the company’s position a dominant one in the market. Since the market for hepatitis drugs is quite big- around 5 percent of the total population suffers from it- Gilead Sciences, Inc. (NASDAQ:GILD) will be making a positive decision from the point of view of sales, profits and revenues.

[KingDMC]

In 72.80 will double down on another drop.

[KingDMC]

Missed a re entry in here dealing with his fractured foot ugh. Nice gains you're making man I love it!

[crudeoil24]

ISIS looking good again today. Maybe we see $75. Huge pipeline, huge milestone payments. Good catalysts here running ISIS to $100.+ this year.

[KingDMC]

Right on. Thanks again for the tip. Doubled down.

[crudeoil24]

I say we close @ 52 week high, or $72.+

[KingDMC]

Doubled down 70.56

[KingDMC]

Missed a double down... Pity

[GuTA]

http://www.prnewswire.com/news-releases/isis-pharmaceuticals-appoints-sarah-boyce-as-chief-business-officer-300015735.html

Very solid hire.

[barnstormer]

Very nice move given the down market today - between the Janssen announcement and Cramer touting on CNBC this AM and stating he's interviewing the ISIS CEO on his show later today a double boost. Suspect the share price will run up into the end of the day, but expect some pull back from the high tomorrow or the day after.

[crudeoil24]

CEO of ISIS on MAD MONEY TONIGHT>

[crudeoil24]

ISIS going to runnnnn today! Love those exponentially growing milestone payments.

[crudeoil24]

Cramer loves this company. Every time he mentions ISIS, we see another spike.

[crudeoil24]

ISIS is a great $$$$$ opportunity.